Fig. 1

MUC20 is downregulated in proteasome inhibitor-resistant MM cell lines and patients. A Heatmap displaying differently expressed RNAs between PI-resistant MM cell lines treated with CFZ or BTZ and PI-sensitive MM cell lines. B MUC20 mRNA level detected in PI-resistant MM cell lines treated with CFZ or BTZ and PI-sensitive MM cell lines. C MUC20 protein level detected in PI-resistant MM cell lines treated with CFZ or BTZ and PI-sensitive MM cell lines. D MUC20 expression profiles of CD138 + bone marrow plasma cells in HDs and patients with MM collected from GEO. E Representative images of flow cytometric analysis for MUC20 and MUC20 expression profiles of CD138 + bone marrow plasma cells in HDs and patients with MM collected from GEO. PS: proteasome inhibitor-sensitive MM cells; PR: proteasome inhibitor-resistant MM cells; CFZ: carfilzomib; BTZ: bortezomib; HD: healthy donors; MGUS: monoclonal gammopathy of undetermined significance MM patients; SMM: smoldering MM patients; NDMM: newly diagnosed MM patients; tMM: PI-sensitive MM patients; VTD: thalidomide and dexamethasone; RRMM: relapsed/refractory MM patients. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001